Maravai LifeSciences (NASDAQ:MRVI) Shares Up 5.2% - Still a Buy?

Key Points

• Maravai LifeSciences shares increased by 5.2% to $3.55, but the trading volume declined significantly, down 77% from the average session.
• Brokerages have mixed opinions on the stock, with three analysts issuing a Buy rating, while Weiss Ratings maintained a "sell" rating, and Royal Bank of Canada reduced their target price from $7.00 to $5.00.
• The company has a market capitalization of $889.94 million, with a negative price-to-earnings ratio of -2.56 and a high debt-to-equity ratio of 0.68.

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) shares shot up 5.2% during trading on Thursday . The company traded as high as $3.53 and last traded at $3.55. 507,210 shares traded hands during trading, a decline of 77% from the average session volume of 2,206,618 shares. The stock had previously closed at $3.37.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on MRVI. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Maravai LifeSciences in a research report on Tuesday. Royal Bank Of Canada decreased their target price on shares of Maravai LifeSciences from $7.00 to $5.00 and set an "outperform" rating for the company in a research report on Tuesday, August 12th. Three analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $5.22.

Maravai LifeSciences Trading Up 3.4%

The stock has a market capitalization of $889.94 million, a price-to-earnings ratio of -2.56 and a beta of 0.33. The company's 50 day moving average is $2.70 and its 200 day moving average is $2.39. The company has a debt-to-equity ratio of 0.68, a quick ratio of 4.49 and a current ratio of 5.16.

Hedge Funds Weigh In On Maravai LifeSciences

Several large investors have recently bought and sold shares of the stock. Callan Family Office LLC acquired a new position in shares of Maravai LifeSciences in the 2nd quarter valued at $25,000. Ethic Inc. bought a new stake in Maravai LifeSciences during the 2nd quarter worth about $26,000. McAdam LLC bought a new stake in Maravai LifeSciences during the 1st quarter worth about $31,000. EntryPoint Capital LLC bought a new stake in Maravai LifeSciences during the 1st quarter worth about $32,000. Finally, Prudential Financial Inc. bought a new stake in Maravai LifeSciences during the 2nd quarter worth about $36,000. 50.25% of the stock is currently owned by institutional investors and hedge funds.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.